Sterilization efficacy of a warm-air circulation system in a vaporized hydrogen peroxide sterilizer Authors: Mi Suk Noh, Su Yeon Lee, Eun Gyu Lee, Jonghyun Shin, Sang-Il Lee, Bong-Hyun Jun, Shengqian Sun, Shengqian Sun, Shengqian Sun, Shengqian Sun Published: 2026 ABSTRACT BackgroundVaporized hydrogen peroxide (VH2O2) sterilization is a widely recognized method for low-temperature sterilization of medical devices. To overcome limitations associated with residual moisture and maximize sterilization efficacy, the integration of a warm-air circulation system (WACS) is proposed as a robust solution.ObjectiveThis study aimed to evaluate the effects of the WACS by comparing temperature uniformity and moisture removal with and without its operation. Additionally, the study assessed whether the WACS contributes to effective sterilization under conditions involving complex medical devices.MethodsTemperature variations within the sterilization chamber and medical devices were monitored using sensors. The impact of the WACS on sterilization efficacy was assessed by introducing artificial moisture to the loading packages in cycles performed with and without the system. Sterilization efficacy was assessed through tests with various items, including process challenge devices (PCDs), flexible and rigid lumens, and dual flexible endoscope dummies.ResultsThe WACS maintained a stable temperature of approximately 55 ~ 60 °C and effectively removed moisture throughout sterilization cycles, ensuring successful sterilization of all items.ConclusionThis study demonstrates that the WACS significantly improves sterilization effectiveness by ensuring uniform temperature and effective moisture removal. This additional system in the VH2O2 sterilizers will enhance the safety and sterilization efficacy of complex medical devices in healthcare settings. Introduction Sterilization is essential for the infection control of medical devices and is strictly regulated by organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) [1,2]. Traditional sterilization relies on high-temperature autoclaving for heat-stable devices [3–5]. While ethylene oxide (EO) gas has been widely used as a low-temperature alternative, it is limited by long cycle times due to aeration and concerns regarding toxicity [3–7]. Consequently, low-temperature vaporized hydrogen peroxide (VH2O2) sterilization has gained importance due to its rapid cycle times and safety profile, as it decomposes into water and oxygen [5–8]. VH2O2 sterilization effectively eliminates microorganisms at low temperatures, protecting delicate devices while ensuring sterility [6–8]. Reusable medical devices require thorough pre-treatment, including cleaning and drying, before low-temperature sterilization to prevent residual moisture that can cause sterilization failure and device damage [9]. Current VH2O2 sterilizers use vacuum during pre-conditioning to remove moisture, but residual moisture often remains [9,10]. Insufficient heat supply during vacuum drying can lead to condensation inside the sterilization chamber, destabilizing hydrogen peroxide vapor distribution and impairing sterilization [9,11,12]. Additionally, cooled external air influx during the ventilation phase induces temperature fluctuations and cold spots, reducing sterilization uniformity [13]. Minimizing hydrogen peroxide vapor condensation and maintaining its concentration are essential for sterilization effectiveness [13,14]. To overcome these challenges, a warm-air circulation system (WACS) was developed, incorporating a fan and heater inside the chamber to distribute warm air evenly and quickly raise chamber temperature. In this study, we propose a method for improving sterilization performance by applying a WACS to avoid reducing sterilization effects and errors during the sterilization process caused by residual moisture in a VH2O2 sterilizer. Evaluation focused on the system’s ability to reduce residual moisture and temperature variation, thereby optimizing VH2O2 sterilization performance for complex medical devices. Materials and methods Ethical statement This study evaluated the sterilization efficacy of a medical device using commercially available biological indicators and standard test soils. The study did not involve human participants, human biological material, or animal subjects. Therefore, approval from an Institutional Review Board (IRB) or ethics committee was not required. Test sterilizers with the WACS We used a VH2O2 sterilization system (Crystal 120M sterilizer, LOWTEM, Korea) equipped with a WACS inside the sterilizer chamber (Fig 1). The WACS consisted of a fan and heater located at the rear of the chamber to raise and equalize the air temperature inside the chamber during the sterilization process. In this system, the fan rotates to force air from the front to the back of the chamber. The air then flows over a heater located directly behind the fan, raising its temperature. The heated air flows back to the front of the fan and then uniformly distributes throughout the entire chamber. This process repeats continuously, ensuring the air inside the chamber circulates and heats up consistently. Schematic diagram of WACS in the test sterilizer. (a) The air heated by the heater is distributed throughout the chamber by convection, induced by the operation of the fan. (b) Appearance of the test sterilizer. (c) WACS mounted on the back side of the chamber. Comparison of temperature changes with and without the WACS Temperature distribution at different chamber locations. The temperature was measured at five locations in the chamber. Temperature sensors (paperless recorder, GP10, YOKOGAWA, Japan) were placed at five locations inside the chamber: front middle, middle, rear middle, top, and bottom, and the WACS was operated for 20 min (S1 Fig a, b). Under the same conditions, the temperature at each position was measured without operating WACS to compare differences in temperature rise. Temperature changes in the medical device. The temperature change of medical scissors in the chamber was examined depending on the operation of the WACS for 20 min (Fig S1 Fig c). A temperature sensor was attached to the hinge of the stainless-steel scissors in the medical device loads, and the scissors with the temperature sensor were placed in the chamber. The temperature of the scissors was measured with the WACS in operation. Under the same conditions, the temperature was measured without the WACS. Residual moisture removal test A total of 24 types of medical devices (S1 Table), composed of both metal and non-metal materials —including stainless steel specula, silicone tubes, PVC tubes, stainless steel scissors, and stainless steel lumens—were individually packaged in sterilization pouches (Perpak™ Sterilization Tyvek Pouch, KM, South Korea, Lot No. 201120-B1, 150 mm x 200M). Each sterilization pouch was injected with 0.5 g of distilled water using a pipette (Research plus variable 100–1000 μL, Eppendorf, Germany). The total amount of water injected into the validation loads was 12 g (S2 Fig a,b). Before sterilization, the total weights of the validation loads, including the added moisture, were measured using a precision balance (initial weight, CF-1000; AND, Japan). The validation loads were then placed on the top and bottom shelves of the sterilizer and processed with a Special Full cycle (54 min). After completing the sterilization process, the weights of the processed validation loads were measured again for comparison with their initial weights. The presence or absence of residual moisture inside each pouch was visually observed after measuring the weight. The difference in weight before and after sterilization indicates the amount of moisture removed by the sterilizer equipped with the WACS. Sterilization efficacy test with the WACS Preparation of test organisms and carriers. In the sterilization efficacy test, Geobacillus stearothermophilus spores (ATCC 7953) were used as the representative biological indicator. Selected in accordance with ISO 11138−1 [15], this organism is highly resistant to vaporized hydrogen peroxide and was inoculated with a population of ≥ 1.0 × 106 spores to validate a Sterility Assurance Level (SAL) of 10−6 as required by ISO 22441 [12]. Since G. stearothermophilus is identified as the most resistant microorganism to vaporized hydrogen peroxide, confirming its inactivation ensures the effective sterilization of the entire load [1,10,12]. Two types of spores were prepared: (i) glass fiber spore discs (GFTS-06, Crosstex, Englewood, Colorado), 2.7 × 106 spores per disc, and (ii) stainless steel wires (0.25 mm × 60 mm) inoculated with a spore suspension (VSG-07, Crosstex, Englewood, Colorado), 2.9 × 106 spores per wire. Recovery method. To confirm the recovery rate of G. stearothermophilus (ATCC 7953, 2.9 × 106/20 μl), inoculated stainless-steel wires (0.25 mm × 60 mm) were used. The procedure followed the guidelines specified in ISO 11737–1:2018, Annex C, Validation of Bioburden Recovery Efficiency [16]. The stainless-steel wire was inoculated with 2.53 × 106 CFU/unit and placed into the eluate. The eluate containing the inoculated wire was vortexed for 5 min. The vortexed sample was transferred to TSA media (Becton, Dickinson and Company, USA) and incubated at 55 ~ 60 °C for 24 hours to observe spore growth (Incubator, DS-DI 150, Dongseo Science Co., Ltd). Three trials were conducted, and the average recovery was calculated. Sterilization efficacy tests for flexible PCDs and flexible lumens with and without the WACS under residual moisture conditions Sterilization efficacy under residual moisture conditions. Each item to be sterilized was individually packaged in a sterilization pouch, and water (0.5 g) was injected into the sterilization pouch containing the item. The prepared items were processed with test flexible PCDs (Process Challenge Device, one-sided open type, 2 mm inner diameter × 1,500 mm in length) and flexible lumens (straight type, 1 mm inner diameter × 2,000 mm in length) in Fig 3a. The specific experimental conditions for the sterilization cycles with and without the WACS were established as follows: With WACS: a biological indicator (BI) disc (glass fiber disc, inoculated with 2.7 × 106/disc, GKE, Germany) was inserted into the head of the test flexible PCD. Ten flexible PCDs, each containing a BI disc, were placed alongside the moisture-loaded items in validation trays to be exposed to a half-cycle of the VH2O2 sterilization process. After completing the cycle, the BI discs were removed from the test flexible PCDs, transferred to TSB media (Becton, Dickinson and Company, USA), and incubated at 55 ~ 60 °C for 7 days to check for bacterial growth. Similarly, stainless steel wires inoculated with 2.9 × 106 spores were inserted into flexible lumens and subjected to sterilization with moisture-loaded items. With WACS: a biological indicator (BI) disc (glass fiber disc, inoculated with 2.7 × 106/disc, GKE, Germany) was inserted into the head of the test flexible PCD. Ten flexible PCDs, each containing a BI disc, were placed alongside the moisture-loaded items in validation trays to be exposed to a half-cycle of the VH2O2 sterilization process. After completing the cycle, the BI discs were removed from the test flexible PCDs, transferred to TSB media (Becton, Dickinson and Company, USA), and incubated at 55 ~ 60 °C for 7 days to check for bacterial growth. Similarly, stainless steel wires inoculated with 2.9 × 106 spores were inserted into flexible lumens and subjected to sterilization with moisture-loaded items. Without WACS: a BI disc (glass fiber disc, inoculated with 1.0 × 106/disc, GKE, Germany) was inserted into the head of the test flexible PCD. Ten flexible PCDs, each containing a BI disc, were placed alongside the moisture-loaded items in validation trays to be exposed to a half-cycle of the VH2O2 sterilization process. After completing the cycle, the BI discs were removed from the test flexible PCDs, transferred to TSB media (Becton, Dickinson and Company, USA), and incubated at 55 ~ 60 °C for 7 days to check for bacterial growth. Similarly, stainless steel wires inoculated with 2.2 × 106 spores/10 μL (True indicating, USA) were inserted into flexible lumens and subjected to sterilization with moisture-loaded items. Without WACS: a BI disc (glass fiber disc, inoculated with 1.0 × 106/disc, GKE, Germany) was inserted into the head of the test flexible PCD. Ten flexible PCDs, each containing a BI disc, were placed alongside the moisture-loaded items in validation trays to be exposed to a half-cycle of the VH2O2 sterilization process. After completing the cycle, the BI discs were removed from the test flexible PCDs, transferred to TSB media (Becton, Dickinson and Company, USA), and incubated at 55 ~ 60 °C for 7 days to check for bacterial growth. Similarly, stainless steel wires inoculated with 2.2 × 106 spores/10 μL (True indicating, USA) were inserted into flexible lumens and subjected to sterilization with moisture-loaded items. Rigid lumen sterilization test. Ten sets of narrow stainless steel lumens—one with an inner diameter of 1 mm and a length of 500 mm, and the other with 0.7 mm inner diameter and 500 mm—were prepared (Fig 3b). A wire BI carrier (0.25 mm outer diameter × 60 mm length, inoculated with 2.9 × 106 spores) was inserted into each stainless-steel lumen, and the lumens were individually packaged in sterilization pouches. The prepared lumens were then divided into two validation trays, with five lumens per tray. These validation trays were subsequently loaded into the sterilizer for a half-cycle sterilization process. After completing the process, the BI wire carriers were removed from the test lumens and transferred to tubes containing 10 ml of TSB medium. The media tubes were then incubated at 55 ~ 60 °C for 7 days to observe microbial growth. Process challenge device (PCD) test under worst-case conditions. Ten sets of one-sided open PCDs—one with a 1 mm inner diameter and 1,500 mm length, and the other with a 2.0 mm inner diameter and 1,500 mm length—were prepared. Each PCD contained a glass fiber BI disc inoculated with 2.7 × 106 G. stearothermophilus spores. The PCDs were loaded into the sterilizer chamber along with six sets of challenge packs (Micro Instrument Case, Sungkwang Meditech Co., Ltd., South Korea), which included two silicone mats to simulate worst-case conditions (Fig 3c). After completing the half-cycle sterilization process, the spore discs inserted inside the test PCDs were transferred to tubes containing 10 ml of TSB. The media tubes were then incubated at 55 ~ 60 °C for 7 days to observe microbial growth. Dual-channel flexible endoscope sterilization test. The sterilization efficacy on a dual-channel flexible endoscope using an endoscope surrogate device (“SPO-PRO” Version 2.0, Spypach, Austria) was validated. The dual-channel surrogate device had one with a 1.0 mm inner diameter × 990 mm in length, and the other with a 1.0 mm inner diameter × 850 mm in length. Three glass fiber BI discs, each inoculated with 2.7 × 106 G. stearothermophilus spores, were inserted into the BI chamber of the surrogate device (Fig 3d). The device was then placed in a sterilization tray and double-wrapped with a sterilization wrap. The tray was positioned at the bottom of the sterilization chamber, and a half-cycle sterilization process was performed (Fig 3e). After the process was completed, the spore discs were removed and transferred to TSB media. The media tubes were incubated at 55 ~ 60 °C for 7 days to observe microbial growth. Statistical analysis. All measurements were independently repeated three times. Quantitative results were summarized as mean ± standard deviation (SD), and statistical differences between conditions were evaluated using an independent Student’s t-test. A p-value of < 0.05 was considered statistically significant, and highly significant differences (p < 0.001) were noted where applicable. All statistical analyses were performed using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). Results Comparison of temperature variation with and without the WACS Temperature changes at different chamber locations. With the WACS (Fig 2a), the temperature was more consistent across different locations, with the maximum temperature difference of 8.3 °C at the start point and as low as 0 °C after 20 minutes. In addition, as time progressed, the temperature difference between the top and bottom locations decreased significantly, indicating the effective circulation of warm air (S2 Table). The temperatures measured at all five locations inside the chamber for 30 minutes increased uniformly, with no difference between locations. Without the WACS (Fig 2b), however, the temperature difference between locations is much larger, starting at 19.4 °C and gradually decreasing to 11.1 °C after 20 minutes (S2 Table). This indicated less uniform heating and a higher variation in temperature across different positions inside the chamber. Temperature changes by locations and the hinge of scissors loaded along with medical devices in the chamber. Temperature changes by locations in the chamber with (a) or without operation of the WACS (b) were measured. Temperature changes of the hinge of scissors loaded along with medical devices inside the chamber were measured (c) with or (d) without operation of the WACS. The results demonstrated that the WACS facilitated uniform temperature distribution across all positions within the chamber. Temperature of the medical device. With the WACS (Fig 2c), the surface temperature of the scissors increased within the first 5–10 minutes, rising to 52.0 °C at 10 minutes. After 20 minutes, the temperature reached 57.3 °C, closely matching the chamber temperature. This indicated the efficiency of WACS for the loaded items (S3 Table). Without the WACS (Fig 2d), however, the temperature increase was significantly slower, reaching only 35.8 °C after 20 minutes, which is 21.5 °C lower than with the WACS. Over 20 minutes of performance, the total temperature increase was just 11.7 °C, reflecting the less effective heating of the device without the WACS (S3 Table). A higher temperature increase in the items to be sterilized can more effectively remove the remaining moisture. Thus, the WACS, which increases the temperature rapidly for the initial 5 minutes, provides a favorable thermal environment that may help mitigate the potential condensation of hydrogen peroxide gas. Residual moisture removal efficacy Residual moisture removal efficacy was confirmed by measuring and comparing the total weight of validation loads before and after sterilization. The validation loads consisted of 24 metal and non-metal medical devices (S1 Table), each packaged in a pouch containing 0.5 g of distilled water (total 12 g of moisture) before and after the sterilizer by Special Full cycle with the WACS. As shown in Table 1, the weights of the loads were measured before and after the sterilization cycles. The system with WACS achieved a mean moisture reduction of 12.92 ± 0.43 g, which was significantly higher than the 8.10 ± 0.13 g reduction observed without WACS (p < 0.001). The total weight reduction of 12.92 g slightly exceeded the 12 g of intentionally injected water, which is likely attributable to the evaporation of intrinsic residual moisture initially present within the complex internal structures of the validation loads. 10.1371/journal.pone.0347533.t001Table 1Moisture reduction before and after sterilization process with and without a WACS.WACS ConditionInitial Weight (g)Weight after Sterilization (g)Moisture Reduction (g)With2006.74 ± 3.461993.82 ± 3.5112.92 ± 0.43***Without2004.42 ± 4.751996.32 ± 4.628.10 ± 0.13Data are presented as mean ± standard deviation (SD) of three independent replicates (n = 3). *** Indicates a significant difference compared to the ‘Without WACS’ group (p < 0.001, Student’s t-test). Moisture reduction before and after sterilization process with and without a WACS. Data are presented as mean ± standard deviation (SD) of three independent replicates (n = 3). *** Indicates a significant difference compared to the ‘Without WACS’ group (p < 0.001, Student’s t-test). In addition, the visual inspection of the medical devices inside the pouch after each sterilization cycle revealed no residual moisture or condensation. This observation was corroborated by the weight reduction data, confirming the complete removal of the added moisture. The WACS completely removed added moisture from the pouched loads during sterilization cycles, leaving no visible residue. This demonstrates that the system effectively eliminates moisture from sterilized items and prevents issues like incomplete drying, condensation, and potential sterilization failure. Sterilization efficacy tests for flexible PCDs and flexible lumens with and without the WACS under residual moisture conditions Sterilization efficacy for items containing residual moisture. The sterilization efficacy was verified with G. stearothermophilus spores under the sterilization half-cycle with added moisture conditions, using two types of sterilization evaluation accessories: (a) flexible PCDs and (b) flexible lumens (Fig 3a). The numbers of surviving test organisms after sterilization with and without WACS are shown in Table 2. The bioburden recovery efficiency of G. stearothermophilus spores (ATCC 7953, 2.9 × 106/20 ml) was measured at about 95% in three reproductive tests. 10.1371/journal.pone.0347533.t002Table 2Comparison of sterilization efficacy for flexible PCDs and lumens with and without the WACS under residual moisture conditions.WACSRepeatABPCNCWith(A: Flexible PCDs,B: Flexible lumens)10/100/101/10/120/100/101/10/130/100/101/10/1Without(A: Flexible PCDs,B: Flexible lumens)110/104/101/10/1210/102/101/10/1310/102/101/10/1Data are presented as (No. of positive cultures) / (Total no. of samples). A positive result indicates bacterial growth and signifies a non-sterile condition. Abbreviations: PC, positive control; NC, negative control. Comparison of sterilization efficacy for flexible PCDs and lumens with and without the WACS under residual moisture conditions. Data are presented as (No. of positive cultures) / (Total no. of samples). A positive result indicates bacterial growth and signifies a non-sterile condition. Abbreviations: PC, positive control; NC, negative control. Diverse PCDs, flexible endoscope with inserted BIs for sterilization efficacy tests. (a) Two types of items with residual moisture: flexible PCD (upper: one side open type, 2 mm inner tube × 1,500 mm in length) and flexible lumens (lower: straight type, 1 mm inner tube × 2,000 mm in length); (b) Rigid lumen (1 mm inner tube × 500 mm in length); (c) PCDs with challenge packs (right side) for sterilization efficacy tests; (d) Dual-channel flexible endoscope with inserted BI discs placed inside the chamber (e). For sterilization with WACS, (i) glass-fiber BI discs inoculated with G. stearothermophilus spores, inserted into 10 flexible PCDs of 2 mm × 1,500 mm, loaded into two sterilization trays containing 11 kg of medical devices with added moisture, all showed negative results for growth after undergoing sterilization half-cycles. No bacteria were observed in the negative control group without the inoculated BI discs, whereas bacteria were observed in the positive control group with non-sterilized BI discs. (ii) The stainless-steel wires inoculated with G. stearothermophilus spores were inserted into 10 flexible lumens of 1 mm × 2,000 mm loaded in two sterilization trays, including 11 kg of medical devices with added moisture, and were all found to have negative growth results after sterilization half-cycles. No bacteria were observed in the negative control group with un-inoculated wires. In contrast, bacteria were observed in the positive control group with non-sterilized wires after inoculation. For sterilization without WACS, (i) glass-fiber BI discs inoculated with G. stearothermophilus spores, inserted into 10 flexible PCDs of 2 mm × 1,500 mm, loaded into two sterilization trays containing 11 kg of medical devices with added moisture, all showed positive results for growth after undergoing sterilization half-cycles. No bacteria were observed in the negative control group without the inoculated BI discs, whereas bacteria were observed in the positive control group with non-sterilized BI discs. (ii) The stainless-steel wires inoculated with G. stearothermophilus spores were inserted into 10 flexible lumens of 1 mm × 2,000 mm loaded in two sterilization trays, including 11 kg of medical devices with added moisture, and were found to have positive growth in 2–4 out of 10 replicates after sterilization half-cycles. No bacteria were observed in the negative control group with un-inoculated wires. In contrast, bacteria were observed in the positive control group with non-sterilized wires after inoculation. Specifically, in the half-cycles without the WACS, the flexible PCDs exhibited a 100 % failure rate, with bacterial growth observed in all samples (30/30) across three independent trials. The flexible lumens showed inconsistent efficacy, with growth detected in 2–4 samples out of 10 in each trial (8/30 growth). In contrast, the half-cycles with the WACS successfully achieved complete inactivation (0/30 growth) for both flexible PCDs and flexible lumens, demonstrating consistent sterilization efficacy regardless of the device type. Sterilization efficacy tests for various PCDs and flexible endoscopes with the WACS Tests were conducted to validate the sterilization efficacy of the WACS-integrated system against highly challenging medical devices, including complex flexible endoscopes and narrow lumens, which represent the critical targets for advanced VH2O2 sterilization. Rigid lumen test. The sterilization efficacy of rigid lumens (Fig 3b) validated with G. stearothermophilus spores under the sterilizer by half-cycle conditions is shown in Table 3. The stainless-steel wires inoculated with G. stearothermophilus spores, inserted into 10 each of the 1 mm × 500 mm and 0.7 mm × 500 mm stainless steel rigid lumens loaded in two sterilization trays, were found to have negative results for growth when incubated for 7 days at 55 ~ 60 °C after the sterilization half-cycles. Under the same incubation conditions, no bacteria were observed in the negative control group with un-inoculated wires. In contrast, bacteria were observed in the positive control group with non-sterilized wires after inoculation. 10.1371/journal.pone.0347533.t003Table 3Sterilization efficacy results for rigid lumens and flexible PCDs.WACSRepeatABPCNCRigid Lumens(A: 1 mm x 500 mmB: 0.7 mm x 500 mm)10/100/101/10/120/100/101/10/130/100/101/10/1Flexible PCDs(A: 1 mm x 1,500 mmB: 2 mm x 1,500 mm)10/100/101/10/120/100/101/10/130/100/101/10/1Data are presented as (No. of positive cultures) / (Total no. of samples). A positive result indicates bacterial growth and signifies a non-sterile condition. Abbreviations: PC, positive control; NC, negative control. Sterilization efficacy results for rigid lumens and flexible PCDs. Data are presented as (No. of positive cultures) / (Total no. of samples). A positive result indicates bacterial growth and signifies a non-sterile condition. Abbreviations: PC, positive control; NC, negative control. PCD testing under worst-case conditions. The sterilization efficacy of the PCDs (Fig 3c) under the worst-case condition, validated with G. stearothermophilus spores under the sterilizer by half-cycle condition, is shown in Table 3. The glass-fiber BI discs, inoculated with G. stearothermophilus spores, were inserted into 10 each of the 1 mm × 1,500 mm and 2 mm × 1,500 mm flexible PCDs, loaded along with six sets of challenge packs containing two silicone mats each, and were found to be nonviable during 7-day incubation period at 55 ~ 60 °C after undergoing sterilization half-cycles. Under the same incubation conditions, no bacteria were observed in the negative control group without inoculated BI discs, whereas bacteria were observed in the positive control group with non-sterilized BI discs. Dual-channel flexible endoscope sterilization test. The sterilization efficacy of the dual-channel flexible endoscope (Fig 3d, 3e) using an endoscope surrogate device validated with G. stearothermophilus spores under the sterilizer by half-cycle conditions is shown in Table 4. Three glass-fiber BI discs, inoculated with G. stearothermophilus spores, inserted into the BI chamber of the surrogate device loaded in a sterilization tray, and double-wrapped with sterilization wraps, showed no viability during the 7-day incubation period at 55 ~ 60 °C after the sterilization half-cycles. Under the same incubation conditions, no bacteria were observed in the negative control group without inoculated BI discs, whereas bacteria were observed in the positive control group with non-sterilized BI discs. 10.1371/journal.pone.0347533.t004Table 4Sterilization efficacy results for dual-channel flexible endoscopes.TypesRepeatABCPCNCDual-channel flexible endoscopes(A: BI chamber #1,B: BI chamber #2,C: BI chamber #3)10/10/10/11/10/120/10/10/11/10/130/10/10/11/10/1Data are presented as (No. of positive cultures) / (Total no. of samples). A positive result indicates bacterial growth and signifies a non-sterile condition. Abbreviations: PC, positive control; NC, negative control. Sterilization efficacy results for dual-channel flexible endoscopes. Data are presented as (No. of positive cultures) / (Total no. of samples). A positive result indicates bacterial growth and signifies a non-sterile condition. Abbreviations: PC, positive control; NC, negative control. Discussion Sterilization is essential for the safety of medical devices, with single-use medical devices and reusable devices requiring validated methods per manufacturer guidelines [17–22]. Due to the carcinogenicity of ethylene oxide (EO), vaporized hydrogen peroxide (VH2O2) sterilization is preferred for delicate instruments [3,4,6,7]. However, as VH2O2 systems are highly sensitive to humidity, which can cause vapor condensation and compromise sterilization, thorough humidity removal is vital for efficacy [10,23–25]]. Therefore, this study assessed the effect of introducing a warm-air circulation system (WACS) to promote moisture removal and optimize sterilization efficiency in VH2O2 processes. The WACS in VH2O2 processes significantly improved temperature uniformity inside the sterilization chamber, eliminating cold spots that impair sterilization, especially in complex device structures. Specifically, by rapidly increasing the temperature during the initial phase (e.g., the first 5 minutes), the WACS provides a favorable thermal environment that effectively mitigates the potential condensation of hydrogen peroxide gas. Moisture removal was enhanced, as demonstrated by weight loss measurements, confirming effective mitigation of residual moisture. Notably, the comparative tests under residual moisture conditions highlighted the differing levels of challenge presented by the devices. The flexible PCDs resulted in total sterilization failure (100% growth) without the WACS, whereas the flexible lumens showed partial and inconsistent failures (20–40% growth). This confirms that the fabricated flexible PCDs effectively simulate a worst-case scenario that is more rigorous than standard lumens. Most importantly, the WACS successfully overcame these challenging conditions, ensuring complete sterility for both the highly resistant PCDs and the variable lumens, thereby eliminating the risk of inconsistent sterilization outcomes caused by residual moisture. This elimination of inconsistency has profound clinical implications. Previous studies have emphasized that residual moisture in complex channels can freeze during the vacuum phase, blocking narrow lumens and hindering the efficient contact of the sterilant with microorganisms [9]. Consequently, this mechanism directly leads to load non-sterility. By actively removing this residual moisture, the WACS provides a critical ‘safety margin,’ preventing issues such as condensation and potential sterilization failures associated with incomplete drying. Various devices, including complex lumens and endoscopes, achieved complete sterilization even under challenging conditions verified by BIs. Recent reviews indicate that ensuring sterilant penetration into narrow lumens remains a significant challenge for conventional systems, as residual moisture can physically obstruct these pathways [9]. Our results demonstrate that the WACS facilitates effective vapor penetration even in these difficult-to-sterilize geometries, expanding the applicability of VH2O2 sterilization to more complex and challenging medical devices. Finally, regarding material safety, the WACS ensures stability by maintaining the temperature below 60°C. This aligns with the ISO 22441 standard for low-temperature sterilization [12]. As supported by comprehensive reviews, this low-temperature profile is fully compatible with heat-sensitive medical polymers and adhesives used in flexible endoscopes [10]. Thus, the system ensures material compatibility and device stability while delivering robust sterilization efficacy for complex geometries that are typically difficult to sterilize with conventional VH2O2 systems. Conclusion This study demonstrates that WACS significantly enhances the reliability and effectiveness of VH2O2 sterilization by addressing key challenges related to moisture and temperature variability. Notably, the process was confirmed to achieve a Sterility Assurance Level (SAL) of 10−6 even under defined challenge conditions. Consequently, this technology shows great potential for improving the safety and consistency of sterilizing complex medical devices and for supporting effective reprocessing practices in healthcare settings. Supporting information Location of temperature sensors in the chamber and on medical devices. (a) Top view of the chamber (sensor positions: a. front, b. middle, c. rear). (b) Front view of the chamber (sensor positions: d. top, e. bottom). (c) A temperature sensor attached to the hinge surface of surgical scissors within the medical device load. (TIF) Experimental setup for the residual moisture removal test. (a) Preparation of representative medical device packages injected with water to simulate wet conditions (see S1 Table for the full list of 24 devices). (b) Configuration of the medical device load inside the sterilization chamber. This setup was used to visually verify moisture reduction efficiency with and without the Warm-Air Circulation System (WACS). (TIF) List of 24 types of medical devices used in the residual moisture removal test and the sterilization efficacy test. Details include the device name, manufacturer, and material composition. (DOCX) Comparison of continuous temperature changes by location in the chamber. Data confirms temperature profiles with and without the Warm-Air Circulation System (WACS). (DOCX) Comparison of continuous temperature changes at the scissor hinge. Data represents temperature monitoring at the hinge of scissors loaded inside the chamber, with and without the WACS. (DOCX) 17 Nov 2025 -->PONE-D-25-51990-->-->Sterilization efficacy of a warm-air circulation system in a vaporized hydrogen peroxide sterilizer-->-->PLOS ONE Dear Dr. Jun, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jan 01 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Shengqian Sun Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating in your Funding Statement: “This study was supported by the Ministry of SMEs and Startups (Grant No. S2634352), South Korea.” Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf. 3. Thank you for stating the following financial disclosure: “This study was supported by the Ministry of SMEs and Startups (Grant No. S2634352), South Korea.” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 4. Thank you for stating the following in the Acknowledgments Section of your manuscript: “This study utilized test results provided by the Korea Testing Certification Institute (KTC, South Korea). Products and the sterilizer were provided by LowTem Co., Ltd. (South Korea). This study was supported by the Ministry of SMEs and Startups (Grant No. S2634352), South Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” We note that you have provided funding information that is currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: “This study was supported by the Ministry of SMEs and Startups (Grant No. S2634352), South Korea.” Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 5. Thank you for stating the following in the Competing Interests section: “The authors have read the journal’s policy and declare the following competing interests: Some of the authors (Su Yeon Lee, Eun Gyu Lee, and Sang-Il Lee) are employees of LOWTEM Co., Ltd., which provided products and the sterilizer used in this study. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors have declared that no competing interests exist.” We note that one or more of the authors are employed by a commercial company: LOWTEM Co., Ltd., a. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form. Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement. b. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. 6. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 7. We note that Figure 1in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright. We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission: a. You may seek permission from the original copyright holder of Figures 1 to publish the content specifically under the CC BY 4.0 license. We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text: “I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.” Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission. In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].” b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only. 8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 9. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Partly Reviewer #2: Partly ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: N/A Reviewer #2: No ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: No Reviewer #2: No ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Dear authors, thank you very much for giving me the opportunity to read your manuscript on the implementation of a warm-air circulation system for vapourised H₂O₂ sterilisation. It is a well-structured and extremely well-presented study. I do, however, have two major points of critique which I believe require addressing before publication. I also have a few smaller suggestions that I believe would improve the manuscript. Major points: - In my view, the efficacy tests (Figs 3 and 4) should include a control with the WACS turned off. For a device used in clinical practice, the expected result would be the inactivation of all test organisms, but without the tests, this cannot be ascertained. This could be an opportunity to demonstrate that efficacy is improved with the WACS. - Currently, the manuscript lacks a discussion in the classical sense. You rightly state that effective sterilisation is important and that WACS seems beneficial. But what are the overarching implications? How often are medical devices currently insufficiently sterilised, and how would implementing a WACS change that? Do you expect the rate of healthcare-associated infections to decrease? Using a WACS seems to lead to higher temperatures of the medical devices – could this cause stability issues? Could one reduce the overall temperature and save energie or the sterilization time to save time? Minor Points: Introduction - You introduced the abbreviation WACS in the abstract, please introduce it once again in the introduction. Methods - Please provide a list of the 24 types of medical device used in the supplements. Ideally, include the manufacturer and material information to help identify which devices are compatible with this setup, especially given the increased temperature of the devices. - Just to make sure it is not a typo - for G. stearothermophilus you used 59°C and for the biological indicators 58°C? Supporting Information - Table S2 is missing. Interesting (but by no means necessary): - With the overall benefits of the WACS, it would be interesting to test reduced cycle times with regard to sterilisation efficacy. Reviewer #2: The experimental design has major defaults; it must be improved. Line numbers should be added. "Preparation of test organisms and carriers Two types of spores were prepared: (i) glass fiber spore discs (GFTS-06, Crosstex, Englewood, Colorado), 2.7×106 spores per disc, and (ii) stainless steel wires (0.25 mm×60 mm) inoculated with a spore suspension (VSG-07, Crosstex, Englewood, Colorado), 2.9×106 spores per wire." Any reference for the spore load applied for the sterilization efficacy test? Also, the spores' dose-dependent effect should be tested; at least two or three spore loads should be implemented for the test. Table 1. There is no need to show each replicate; please present the data in the style of average ± standard deviation. Also, significant differences, a t-test, or LSD should be added for the data comparison. The method should also include statistical analysis. Fig.3. It is very confusing for the y-axis; the % growth, actual microorganism load should be presented, instead of %. Also, it is not reasonable that all of the growth for the + control shows 100% growth. Dose-dependent effect should be analyzed. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 28 Jan 2026 We have provided a detailed, point-by-point response to all reviewer and editor comments in the attached “Response to Reviewers” document. All suggested revisions have been carefully addressed, and corresponding changes have been incorporated into the revised manuscript. Changes in the manuscript are shown using track changes for clarity. We thank the Editor and Reviewers for their constructive comments, which have helped to improve the quality of our manuscript. Submitted filename: Response to Reviewers_v2.docx 25 Mar 2026 -->PONE-D-25-51990R1-->-->Sterilization efficacy of a warm-air circulation system in a vaporized hydrogen peroxide sterilizer-->-->PLOS One Dear Dr. Jun, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 09 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Shengqian Sun Academic Editor PLOS One Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #2: All comments have been addressed Reviewer #3: (No Response) ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #2: Yes Reviewer #3: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #2: Yes Reviewer #3: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #2: Yes Reviewer #3: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #2: Yes Reviewer #3: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #2: The manuscript has been greatly revised. And I have no more questions. Thanks for the authors revising. Cheers, Reviewer #3: Line 175: Please check the brackets. Lines 228-230: Here a conclusion is already drawn. The statement about “consistent sterilisation performance“ cannot be drawn from the so presented data alone. The sentence should be removed. Line 240: “A higher temperature increases in the items [..] can [..] remove the [..] moisture.“ Please check the grammar of this sentence. I guess the authors meant “A higher temperature increase…“. Line 242: The so far presented data does not allow a conclusion about the removal of sterilisation inhibitors. The data only allows statements regarding the heating and temperature uniformity. Lines 252-255: Please check the grammar of this paragraph/sentence and split the sentence into two or more shorter sentences. Table 1: With the WACS, 12.92 g of water were removed, but only 12 g of water were added before the WACS-sterilisation. How do the authors explain the additions removal of 0.92 g? Lines 264-266: “This demonstrates that the system effectively eliminates moisture from sterilized items and prevents issues like incomplete drying, condensation, and potential sterilization failure.“ This statement is a conclusion and should not be made in the Results part of the manuscript. Line 301: “after sterilisation half-cycle“ is written twice in the sentence Line 363: There is a full stop set wrongly in the figure text. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #2: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 1 Apr 2026 Dear Academic Editor, We sincerely thank you and the reviewers for your valuable comments and constructive feedback on our manuscript (PONE-D-25-51990R1). We have carefully revised the manuscript according to all comments provided. A detailed, point-by-point response to the reviewers’ comments has been included in the “Response to Reviewers” file. In addition, a marked-up version of the manuscript with tracked changes and a clean revised version have been uploaded. We believe that the manuscript has been significantly improved and is now suitable for publication in PLOS ONE. Thank you for your consideration. Sincerely, Bong-Hyun Jun Submitted filename: Response to Reviewers_revision2.docx 6 Apr 2026 Sterilization efficacy of a warm-air circulation system in a vaporized hydrogen peroxide sterilizer PONE-D-25-51990R2 Dear Dr. Jun, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Shengqian Sun Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #3: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #3: (No Response) ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #3: (No Response) ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #3: (No Response) ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #3: (No Response) ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #3: (No Response) ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #3: No ********** PONE-D-25-51990R2 PLOS One Dear Dr. Jun, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Shengqian Sun Academic Editor PLOS One